amycretin
Recombinant proteinexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 11, 2022 (NCT05369390)
Timeline
Indications
Mechanism of action
GLP1R agonist
Amylin receptor AMY1, CALCR/RAMP1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07121153 | Phase 1 | Aug 11, 2025 | Novo Nordisk |
| NCT06820476 | Phase 1 | Feb 9, 2025 | Novo Nordisk |
| NCT06559527 | Phase 1 | Aug 20, 2024 | Novo Nordisk |
| NCT06542874 | Phase 2 | Aug 7, 2024 | Novo Nordisk |
| NCT06478563 | Phase 1 | Jun 27, 2024 | Novo Nordisk |
| NCT06461039 | Phase 1 | Jun 14, 2024 | Novo Nordisk |
| NCT06064006 | Phase 1/Phase 2 (Phase 2) | Sep 15, 2023 | Novo Nordisk |
| NCT06049329 | Phase 1 | Sep 14, 2023 | Novo Nordisk |
| NCT05369390 | Phase 1 | May 11, 2022 | Novo Nordisk |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 9 | 9 | 2 | 2022 |
1 organizations
Page 1 / 1